RESEARCHER PROFILE
Professor Alice Rumbold (Filmed November 2023)
Perinatal epidemiologist & Co-Theme Leader of
SAHMRI Women and Kids
South Australian Health and Medical Research Institute &
Research Leader, Robinson Research Institute
University of Adelaide
Adelaide, Australia
Professor Alice Rumbold is Theme Leader of SAHMRI Women and Kids, managing a multidisciplinary research team focussed on improving health outcomes for women, babies and families. She also holds an affiliate position as a Research Leader within the Robinson Research Institute at the University of Adelaide.
An epidemiologist and health services researcher, she is internationally renowned for her leadership of large-scale clinical trials, epidemiological studies and systematic review activities to improve perinatal and reproductive health care. She is passionate about improving health outcomes for women and babies, particularly those experiencing vulnerability. Her current research interests include preterm birth, breastfeeding, human milk banking and infertility.
She has held continuous NHMRC funding as a CI since 2007, totalling >$21.2m across 13 grants, including a NHMRC Career Development Fellowship. Her research has generated significant publications in top-ranking journals such as the New England Journal of Medicine, Lancet Global Health, British Journal of Obstetrics and Gynaecology, Human Reproduction and American Journal of Epidemiology, including 11 papers with over 100 citations.
Professor Rumbold’s current research is primarily focused on improving breastfeeding outcomes in preterm babies. She runs several clinical trials that aim to improve breastfeeding outcomes in premature babies, a vulnerable group that is known to have difficulties with establishing breastfeeding. Alice’s research tests new interventions to improve breastfeeding outcomes in these babies, as breast milk is particularly crucial for their development.
Professor Rumbold finds motivation and inspiration from the families participating in her research. These families often participate while knowing that they may not receive direct benefits from the research. She is also driven by the potential to have lifelong impacts on health and opportunities by improving outcomes in the early months of life.
Apart from research, Professor Rumbold loves music. She enjoys listening to it, playing it, and attending live music events. She is a keen cellist and pianist and was previously involved with the Darwin Symphony Orchestra.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
-
Exercise program for the prevention of osteoporotic fracture
Dr Beck is an international leader in the effects of mechanical loading on bone health. Dr Beck graduated from The University of Queensland (BHMS[Ed]) and the University of Oregon (MSc and PhD) and completed a postdoctoral research fellowship in the Stanford University School of Medicine (California, USA.) She is a Professor of Exercise Science at Griffith University Gold Coast campus, where she has led the Bone Densitometry Research Laboratory since 2004.
-
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors).
